XE7C Stock Overview
A clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Cardiff Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.28 |
| 52 Week High | US$5.59 |
| 52 Week Low | US$1.30 |
| Beta | 1.76 |
| 1 Month Change | 100.00% |
| 3 Month Change | 77.23% |
| 1 Year Change | 176.13% |
| 3 Year Change | -25.57% |
| 5 Year Change | 229.23% |
| Change since IPO | -99.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| XE7C | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.7% | 5.8% | 2.0% |
| 1Y | 176.1% | -6.1% | 9.6% |
Return vs Industry: XE7C exceeded the German Biotechs industry which returned -9.8% over the past year.
Return vs Market: XE7C exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| XE7C volatility | |
|---|---|
| XE7C Average Weekly Movement | 28.2% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: XE7C's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: XE7C's weekly volatility has increased from 20% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 32 | Mark Erlander | www.cardiffoncology.com |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers.
Cardiff Oncology, Inc. Fundamentals Summary
| XE7C fundamental statistics | |
|---|---|
| Market cap | €224.35m |
| Earnings (TTM) | -€41.56m |
| Revenue (TTM) | €664.88k |
304.7x
P/S Ratio-4.9x
P/E RatioIs XE7C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XE7C income statement (TTM) | |
|---|---|
| Revenue | US$688.00k |
| Cost of Revenue | US$34.90m |
| Gross Profit | -US$34.21m |
| Other Expenses | US$8.79m |
| Earnings | -US$43.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | -4,973.11% |
| Net Profit Margin | -6,250.73% |
| Debt/Equity Ratio | 0% |
How did XE7C perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 05:21 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cardiff Oncology, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| Sung Ji Nam | Avondale Partners |
| Bryan Brokmeier | Cantor Fitzgerald & Co. |